nach oben

Current Diabetes Reports

Erschienen in:

01.01.2015 | Pediatric Type 2 Diabetes (PS Zeitler, Section Editor)

Morbidity and Mortality in Young-Onset Type 2 Diabetes in Comparison to Type 1 Diabetes: Where Are We Now?

verfasst von: Jencia Wong, Maria Constantino, Dennis K. Yue

Erschienen in: Current Diabetes Reports | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Increasingly, we recognise that type 2 diabetes in youth is a disease with an aggressive time course and a significant complication risk. On the other hand, outcomes for youth with type 1 diabetes appear generally to be improving. With increasing numbers of both types of diabetes in youth, it is timely that a comparative perspective is offered to help clinicians prognosticate more appropriately. Contemporary comparative studies add a new perspective to a consistent story, that for youth-onset type 2 diabetes, the development and progression of cardio-renal complications are increased and the survival prognosis is significantly worse than for type 1 diabetes. Here, we review this mounting evidence, highlight the importance of metabolic syndrome factors in the excess risk and underscore that there remains a significant mortality gap for youth with either type of diabetes, to be addressed as a matter of urgency.

Patterson C, Guariguata L, Dahlquist G, Soltesz G, Ogle G, Silink M. Diabetes in the young—a global view and worldwide estimates of numbers of children with type 1 diabetes. Diabetes Res Clin Pract. 2014;103(2):161–75.PubMedCrossRef

Lam DW, LeRoith D. The worldwide diabetes epidemic. Curr Opin Endocrinol Diabetes Obes. 2012;19(2):93–6.PubMedCrossRef

Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metrics. 2010;8:29.CrossRef

4.•

Imperatore GMDP, Boyle JPPHD, Thompson TJMS, Case DPHD, Dabelea DMD, et al. Projections of type 1 and type 2 diabetes burden in the U.S. population aged <20 years through 2050: dynamic modeling of incidence, mortality, and population growth. Diabetes Care. 2012;35(12):2515–20. This study provides estimates of the future burden of disease in the context of increaing numbers of youth with type 1 and type 2 diabetes.

Dabelea D, Bell RA, D’Agostino Jr RB, Imperatore G, Johansen JM, Linder B, et al. Incidence of diabetes in youth in the United States. JAMA J Am Med Assoc. 2007;297(24):2716–24.CrossRef

Dabelea D, Mayer-Davis EJ, Saydah S, Imperatore G, Linder B, Divers J, et al. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA J Am Med Assoc. 2014;311(17):1778–86.CrossRef

Liese AD, D’Agostino Jr RB, Hamman RF, Kilgo PD, Lawrence JM, Liu LL, et al. The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for Diabetes in Youth Study. Pediatrics. 2006;118(4):1510–8.PubMedCrossRef

8.••

TODAY Study Group, Zeitler P, Hirst K, Pyle L, Linder B, Copeland K, et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. 2012;366(24):2247–56. The TODAY trial is the first RCT examining diabetes management in YT2DM. Publications arising from this trial highlight the severe phenotype in YT2DM, the progressive beta cell decline and progression of risk factors for this patient group.

TODAY Study Group, Copeland KC, Zeitler P, Geffner M, Guandalini C, Higgins J, et al. Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. J Clin Endocrinol Metab. 2011;96(1):159–67.PubMedCentralPubMedCrossRef

10.

TODAY Study Group. Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care. 2013;36(6):1735–41.PubMedCentralCrossRef

11.

TODAY Study Group. Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and beta-cell function in TODAY. Diabetes Care. 2013;36(6):1749–57.PubMedCentralCrossRef

12.

TODAY Study Group. Lipid and inflammatory cardiovascular risk worsens over 3 years in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care. 2013;36(6):1758–64.PubMedCentralCrossRef

13.

TODAY Study Group. Retinopathy in youth with type 2 diabetes participating in the TODAY clinical trial. Diabetes Care. 2013;36(6):1772–4.PubMedCentralCrossRef

14.

Yokoyama H, Okudaira M, Otani T, Takaike H, Miura J, Saeki A, et al. Existence of early-onset NIDDM Japanese demonstrating severe diabetic complications. Diabetes Care. 1997;20(5):844–7.PubMedCrossRef

15.•

Luk AO, Lau ES, So WY, Ma RC, Kong AP, Ozaki R, et al. Prospective study on the incidences of cardiovascular-renal complications in Chinese patients with young-onset type 1 and type 2 diabetes. Diabetes Care. 2014;37(1):149–57. YT2DM is a growing problem in Asia and this large study is one of few that examines diabetes complications specifically in Chinese with obese and non obese YT2DM, in comparison to T1DM.

16.

Hillier TA, Pedula KL. Complications in young adults with early-onset type 2 diabetes: losing the relative protection of youth. Diabetes Care. 2003;26(11):2999–3005.PubMedCrossRef

17.

Wong J, Molyneaux L, Constantino M, Twigg SM, Yue DK. Timing is everything: age of onset influences long-term retinopathy risk in type 2 diabetes, independent of traditional risk factors. Diabetes Care. 2008;31(10):1985–90.PubMedCentralPubMedCrossRef

18.

Pambianco G, Costacou T, Ellis D, Becker DJ, Klein R, Orchard TJ. The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes. 2006;55(5):1463–9.PubMedCrossRef

19.

Miller RG, Secrest AM, Ellis D, Becker DJ, Orchard TJ. Changing impact of modifiable risk factors on the incidence of major outcomes of type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care. 2013;36(12):3999–4006.PubMedCentralPubMedCrossRef

20.

Scott CR, Smith JM, Cradock MM, Pihoker C. Characteristics of youth-onset noninsulin-dependent diabetes mellitus and insulin-dependent diabetes mellitus at diagnosis. Pediatrics. 1997;100(1):84–91.PubMedCrossRef

21.

Eppens MC, Craig ME, Cusumano J, Hing S, Chan AKF, Howard NJ, et al. Prevalence of diabetes complications in adolescents with type 2 compared with type 1 diabetes. Diabetes Care. 2006;29(6):1300–6.PubMedCrossRef

22.

Yokoyama H, Okudaira M, Otani T, Sato A, Miura J, Takaike H, et al. Higher incidence of diabetic nephropathy in type 2 than in type 1 diabetes in early-onset diabetes in Japan. Kidney Int. 2000;58(1):302–11.PubMedCrossRef

23.

Pinhas-Hamiel O, Zeitler P. Acute and chronic complications of type 2 diabetes mellitus in children and adolescents. Lancet. 2007;369(9575):1823–31.PubMedCrossRef

24.•

Dart AB, Sellers EA, Martens PJ, Rigatto C, Brownell MD, Dean HJ. High burden of kidney disease in youth-onset type 2 diabetes. Diabetes Care. 2012;35(6):1265–71. This large study examines the burden of kidney disease and end-stage renal disease using prospectively collected data in YT2DM and type 1 diabetes.

25.

Maahs DM, Snively BM, Bell RA, Dolan L, Hirsch I, Imperatore G, et al. Higher prevalence of elevated albumin excretion in youth with type 2 than type 1 diabetes: the SEARCH for Diabetes in Youth study. Diabetes Care. 2007;30(10):2593–8.PubMedCrossRef

26.

McGrath NM, Parker GN, Dawson P. Early presentation of type 2 diabetes mellitus in young New Zealand Maori. Diabetes Res Clin Pract. 1999;43(3):205–9.PubMedCrossRef

27.

Adelman RD, Restaino IG, Alon US, Blowey DL. Proteinuria and focal segmental glomerulosclerosis in severely obese adolescents. J Pediatr. 2001;138(4):481–5.PubMedCrossRef

28.•

Constantino MI, Molyneaux L, Limacher-Gisler F, Al-Saeed A, Luo C, Wu T, et al. Long-term complications and mortality in young-onset diabetes: type 2 diabetes is more hazardous and lethal than type 1 diabetes. Diabetes Care. 2013;36(12):3863–9. This study utilises a long-term diabetes database to examine the long-term mortality differences in type 1 and type 2 diabetes of equivalent age of onset.

29.

Salardi S, Porta M, Maltoni G, Rubbi F, Rovere S, Cerutti F, et al. Infant and toddler type 1 diabetes: complications after 20 years’ duration. Diabetes Care. 2012;35(4):829–33.PubMedCentralPubMedCrossRef

30.

Donaghue KC, Fairchild JM, Craig ME, Chan AK, Hing S, Cutler LR, et al. Do all prepubertal years of diabetes duration contribute equally to diabetes complications? Diabetes Care. 2003;26(4):1224–9.PubMedCrossRef

31.

Bakris GL, Molitch M. Microalbuminuria as a risk predictor in diabetes: the continuing saga. Diabetes Care. 2014;37(3):867–75.PubMedCrossRef

32.

Ma RC, Chan JC. Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States. Ann N Y Acad Sci. 2013;1281:64–91.PubMedCentralPubMedCrossRef

33.

Sellers EA, Blydt-Hansen TD, Dean HJ, Gibson IW, Birk PE, Ogborn M. Macroalbuminuria and renal pathology in First Nation youth with type 2 diabetes. Diabetes Care. 2009;32(5):786–90.PubMedCentralPubMedCrossRef

34.

Wong J. Is there benefit in dual renin-angiotensin-aldosterone system blockade? No, yes and maybe: a guide for the perplexed. Diabetes Vasc Dis Res Off J Int Soc Diabetes Vasc Dis. 2013;10(3):193–201.CrossRef

35.

Dart AB, Martens PJ, Rigatto C, Brownell MD, Dean HJ, Sellers EA. Earlier onset of complications in youth with type 2 diabetes. Diabetes Care. 2014;37(2):436–43.PubMedCrossRef

36.

Mayer-Davis EJ, Davis C, Saadine J, D’Agostino Jr RB, Dabelea D, Dolan L, et al. Diabetic retinopathy in the SEARCH for Diabetes in Youth Cohort: a pilot study. Diabet Med. 2012;29(9):1148–52.PubMedCrossRef

37.

Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4–7 yr before clinical diagnosis. Diabetes Care. 1992;15(7):815–9.PubMedCrossRef

38.

Jaiswal M, Lauer A, Martin CL, Bell RA, Divers J, Dabelea D, et al. Peripheral neuropathy in adolescents and young adults with type 1 and type 2 diabetes from the SEARCH for Diabetes in Youth follow-up cohort: a pilot study. Diabetes Care. 2013;36(12):3903–8.PubMedCentralPubMedCrossRef

39.

Tesfaye S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu-Tirgoviste C, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005;352(4):341–50.PubMedCrossRef

40.

Duca L, Sippl R, Snell-Bergeon JK. Is the risk and nature of CVD the same in type 1 and type 2 diabetes? Curr Diabetes Rep. 2013;13(3):350–61.CrossRef

41.

Rodriguez BL, Fujimoto WY, Mayer-Davis EJ, Imperatore G, Williams DE, Bell RA, et al. Prevalence of cardiovascular disease risk factors in U.S. children and adolescents with diabetes: the SEARCH for diabetes in youth study. Diabetes Care. 2006;29(8):1891–6.PubMedCrossRef

42.

West NA, Hamman RF, Mayer-Davis EJ, D’Agostino Jr RB, Marcovina SM, Liese AD, et al. Cardiovascular risk factors among youth with and without type 2 diabetes: differences and possible mechanisms. Diabetes Care. 2009;32(1):175–80.PubMedCentralPubMedCrossRef

43.

Gordon SM, Davidson WS, Urbina EM, Dolan LM, Heink A, Zang H, et al. The effects of type 2 diabetes on lipoprotein composition and arterial stiffness in male youth. Diabetes. 2013;62(8):2958–67.PubMedCentralPubMedCrossRef

44.

Whalley GA, Gusso S, Hofman P, Cutfield W, Poppe KK, Doughty RN, et al. Structural and functional cardiac abnormalities in adolescent girls with poorly controlled type 2 diabetes. Diabetes Care. 2009;32(5):883–8.PubMedCentralPubMedCrossRef

45.

Alman AC, Talton JW, Wadwa RP, Urbina EM, Dolan LM, Daniels SR, et al. Cardiovascular health in adolescents with type 1 diabetes: The SEARCH CVD Study. Pediatr Diabetes. 2014;15(7):502–10. doi:10.1111/pedi.12120.

46.

Wadwa RP, Urbina EM, Anderson AM, Hamman RF, Dolan LM, Rodriguez BL, et al. Measures of arterial stiffness in youth with type 1 and type 2 diabetes the SEARCH for diabetes in youth study. Diabetes Care. 2010;33(4):881–6.PubMedCentralPubMedCrossRef

47.

Orchard TJMD. The changing face of young-onset diabetes: type 1 optimism mellowed by type 2 concerns. Diabetes Care. 2013;36(12):3857–9.PubMedCentralPubMedCrossRef

48.

Prevention CfDca. FastStats—deaths and mortality.

49.

Vergouwe Y, Soedamah-Muthu SS, Zgibor J, Chaturvedi N, Forsblom C, Snell-Bergeon JK, et al. Progression to microalbuminuria in type 1 diabetes: development and validation of a prediction rule. Diabetologia. 2010;53(2):254–62.PubMedCentralPubMedCrossRef

50.

Secrest AM, Becker DJ, Kelsey SF, LaPorte RE, Orchard TJ. All-cause mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes: the Allegheny County type 1 diabetes registry. Diabetes Care. 2010;33(12):2573–9.PubMedCentralPubMedCrossRef

51.•

Miller RG, Secrest AM, Sharma RK, Songer TJ, Orchard TJ. Improvements in the life expectancy of type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications study cohort. Diabetes. 2012;61(11):2987–92. The Pittsburgh EDC study is an important population study which provides new evidence for improving outcomes in T1DM.

52.

Jorgensen ME, Almdal TP, Carstensen B. Time trends in mortality rates in type 1 diabetes from 2002 to 2011. Diabetologia. 2013;56(11):2401–4.PubMedCrossRef

53.

Harjutsalo V, Forsblom C, Groop PH. Time trends in mortality in patients with type 1 diabetes: nationwide population based cohort study. BMJ Br Med J. 2011;343:d5364.CrossRef

54.

Morimoto A, Onda Y, Nishimura R, Sano H, Utsunomiya K, Tajima N. Cause-specific mortality trends in a nationwide population-based cohort of childhood-onset type 1 diabetes in Japan during 35 years of follow-up: the DERI Mortality Study. Diabetologia. 2013;56(10):2171–5.PubMedCrossRef

55.

Harding JL, Shaw JE, Peeters A, Guiver T, Davidson S, Magliano DJ. Mortality trends among people with type 1 and type 2 diabetes in Australia: 1997-2010. Diabetes Care. 2014;37(9):2579–86.PubMedCrossRef

56.

Washington RE, Orchard TJ, Arena VC, Laporte RE, Tull ES. Incidence of type 1 and type 2 diabetes in youth in the U.S. Virgin Islands, 2001–2010. Pediatr Diabetes. 2013;14(4):280–7.PubMedCrossRef

57.

O’Grady MJ, Delaney J, Jones TW, Davis EA. Standardised mortality is increased three-fold in a population-based sample of children and adolescents with type 1 diabetes. Pediatr Diabetes. 2013;14(1):13–7.PubMedCrossRef

58.

Orchard TJ, Secrest AM, Miller RG, Costacou T. In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia. 2010;53(11):2312–9.PubMedCentralPubMedCrossRef

59.

Groop PH, Thomas MC, Moran JL, Waden J, Thorn LM, Makinen VP, et al. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes. 2009;58(7):1651–8.PubMedCentralPubMedCrossRef

60.

Allemann S, Saner C, Zwahlen M, Christ ER, Diem P, Stettler C. Long-term cardiovascular and non-cardiovascular mortality in women and men with type 1 and type 2 diabetes mellitus: a 30-year follow-up in Switzerland. Swiss Med Wkly. 2009;139(39–40):576–83.PubMed

61.

Pavkov ME, Bennett PH, Knowler WC, Krakoff J, Sievers ML, Nelson RG. Effect of youth-onset type 2 diabetes mellitus on incidence of end-stage renal disease and mortality in young and middle-aged Pima Indians. JAMA J Am Med Assoc. 2006;296(4):421–6.CrossRef

62.

Rhodes E, Prosser L, Hoerger T, Lieu T, Ludwig D, Laffel L. Estimated morbidity and mortality in adolescents and young adults diagnosed with type 2 diabetes mellitus. Diabet Med. 2012;29(4):453–63.PubMedCrossRef

63.

Waernbaum I, Blohmé G, Östman J, Sundkvist G, Eriksson J, Arnqvist H, et al. Excess mortality in incident cases of diabetes mellitus aged 15 to 34 years at diagnosis: a population-based study (DISS) in Sweden. Diabetologia. 2006;49(4):653–9.PubMedCrossRef

64.

Conway BN, May ME, Signorello LB, Blot WJ. Mortality experience of a low-income population with young-onset diabetes. Diabetes Care. 2012;35(3):542–8.PubMedCentralPubMedCrossRef

65.

Dyck RF, Jiang Y, Osgood ND. The long-term risks of end stage renal disease and mortality among First Nations and non-First Nations people with youth-onset diabetes. Can J Diabetes. 2014;38(4):237–43. doi:10.1016/j.jcjd.2014.03.005.

66.

Merger SR, Leslie RD, Boehm BO. The broad clinical phenotype of type 1 diabetes at presentation. Diabet Med. 2013;30(2):170–8.PubMedCrossRef

67.

Cleland SJ, Fisher BM, Colhoun HM, Sattar N, Petrie JR. Insulin resistance in type 1 diabetes: what is ‘double diabetes’ and what are the risks? Diabetologia. 2013;56(7):1462–70.PubMedCentralPubMedCrossRef

68.

Mottl AK, Lauer A, Dabelea D, Maahs DM, D’Agostino Jr RB, Dolan LM, et al. Albuminuria according to status of autoimmunity and insulin sensitivity among youth with type 1 and type 2 diabetes. Diabetes Care. 2013;36(11):3633–8.PubMedCentralPubMedCrossRef

69.

Linder BL, Fradkin JE, Rodgers GP. The TODAY study: an NIH perspective on its implications for research. Diabetes Care. 2013;36(6):1775–6.PubMedCentralPubMedCrossRef

Titel: Morbidity and Mortality in Young-Onset Type 2 Diabetes in Comparison to Type 1 Diabetes: Where Are We Now?
verfasst von: Jencia Wong
Maria Constantino
Dennis K. Yue
Publikationsdatum: 01.01.2015
Verlag: Springer US
Erschienen in: Current Diabetes Reports / Ausgabe 1/2015
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-014-0566-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2015

Lifestyle Therapy for the Treatment of Youth with Type 2 Diabetes

PCOS in Adolescence and Type 2 Diabetes

Probiotics and Pregnancy

Erratum to: Fine Mapping of Type 2 Diabetes Susceptibility Loci

Metabolic and Glycemic Sequelae of Sleep Disturbances in Children and Adults